2020
Biodistribution and internal radiation dosimetry of a novel probe for thymidine phosphorylase imaging, [123I]IIMU, in healthy volunteers
Watanabe S, Nishijima KI, Okamoto S, Magota K, Hirata K, Toyonaga T, Shiga T, Kuge Y, Tamaki N. Biodistribution and internal radiation dosimetry of a novel probe for thymidine phosphorylase imaging, [123I]IIMU, in healthy volunteers. Annals Of Nuclear Medicine 2020, 34: 595-599. PMID: 32361818, DOI: 10.1007/s12149-020-01469-4.Peer-Reviewed Original ResearchConceptsΜSv/MBqHealthy volunteersOLINDA/EXM 1.1 softwareEffective dosesWhole-body emission scansThymidine phosphorylaseResultsNo adverse eventsHealthy male adultsHigh uptakePotential clinical useMean effective dosesHigh-uptake organsAdverse eventsSingle doseInternal radiation dosimetryBlood samplesRenal systemTime-activity curvesHealthy adultsInjected activityScreening testNew radiotracersClinical useTime pointsMale adults
2014
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Medicine 2014, 3: 293-299. PMID: 24464780, PMCID: PMC3987079, DOI: 10.1002/cam4.164.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerPathological complete responsePositive breast cancerBreast cancerPreoperative capecitabineClinical responseHER2-negative operable breast cancerDihydropyrimidine dehydrogenaseOnly grade 3 toxicityOverall clinical response rateThymidine phosphorylaseGrade 3 responsePartial clinical responsePathological response assessmentsPreoperative chemotherapy regimensClinical response rateComplete clinical responseGrade 3 toxicityOperable breast cancerPhase II studyPalmar-plantar erythrodysesthesiaMetastatic breast cancerTime of surgeryMiller-Payne
2006
Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer
Roy S, Russo S, Black G, Eloubeidi M, Steg A, Zelterman D, Johnson M, Diasio R, Saif M. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. Journal Of Clinical Oncology 2006, 24: 14001-14001. DOI: 10.1200/jco.2006.24.18_suppl.14001.Peer-Reviewed Original ResearchPhase II studyLA pancreatic cancerEfficacy of capecitabinePancreatic cancerII studyTNF-alphaThymidine phosphorylaseGI bleedingDose reductionSix-month survival ratesTP/DPD ratioTNF-alpha mRNA levelsPhase IActivity of capecitabineAdvanced pancreatic cancerGrade 1 anemiaGrade 1 thrombocytopeniaNausea/vomitingPts underwent surgeryEffect of XRTConcurrent XRTStable diseaseUnderwent surgeryMedian survivalPartial response
2005
THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE: PROTEIN EXPRESSION AND GENOTYPE IN PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL
Farrell J, Winter K, Van Rijnsoever M, Regine W, Abrams R, Safran H, Hoffman J, Schaeffer P, Mohiuddin M, Macdonald J, Benson A, Willett C, Elsaleh H. THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE: PROTEIN EXPRESSION AND GENOTYPE IN PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL. Pancreas 2005, 31: 439-440. DOI: 10.1097/01.mpa.0000193663.09525.af.Peer-Reviewed Original Research
1991
Antiviral Activity of 5-Iodo-2’-Deoxyuridine and Related Drugs in Human Keratinocytes Infected in vitro with Herpes simplex Virus Type 1
Reuveni H, Bull CO, Landry ML, Milstone LM, Schwartz PM. Antiviral Activity of 5-Iodo-2’-Deoxyuridine and Related Drugs in Human Keratinocytes Infected in vitro with Herpes simplex Virus Type 1. Skin Pharmacology And Physiology 1991, 4: 291-297. PMID: 1665069, DOI: 10.1159/000210964.Peer-Reviewed Original ResearchConceptsGuinea pig embryo cellsHerpes simplex virus type 1Simplex virus type 1Virus type 1Antiviral activityThymidine phosphorylaseHuman keratinocytesType 1Cutaneous viral infectionsTopical antiviral agentsAntiviral agentsViral infectionExperimental animalsEmbryo cellsRelated drugsIUdRInfected cellsKeratinocytesDrugsCellsActivityInfectionPhosphorylase
1988
Local and Systemic Implications of Thymidine Catabolism by Human Keratinocytesa
SCHWARTZ P, REUVENI H, MILSTONE L. Local and Systemic Implications of Thymidine Catabolism by Human Keratinocytesa. Annals Of The New York Academy Of Sciences 1988, 548: 115-124. PMID: 2470288, DOI: 10.1111/j.1749-6632.1988.tb18798.x.Chapters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply